FRAMINGHAM (02/27/2004) - Genaissance Pharmaceuticals Inc. will acquire Houston-based genomic services company Lark Technologies Inc. in an all-stock transaction valued at approximately US$19.9 million. Carl Balezentis, president and CEO of Lark, will join Genaissance as senior vice president and remain president of Lark Technologies. The transaction is expected to close in the first half of this year.
- Free Whitepaper! The 5 criteria to help you select the right analytics platform for your organization.
- Free Whitepaper! Learn how IT is evolving from producer to enabler, and fostering collaboration around analytics.
- Free Whitepaper! Learn how to create an analytics environment that is governed, scalable and self-serve.